Get the Stockscreener App
244.67
1.49%
-3.71
Pre-market:
245.17
0.50
+0.20%
Insulet Corporation stock is traded at $244.67, with a volume of 757.99K.
It is down -1.49% in the last 24 hours and down -13.27% over the past month.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.
See More
Previous Close:
$248.38
Open:
$247.58
24h Volume:
757.99K
Relative Volume:
1.20
Market Cap:
$17.18B
Revenue:
$1.98B
Net Income/Loss:
$420.90M
P/E Ratio:
41.90
EPS:
5.84
Net Cash Flow:
$218.20M
1W Performance:
-5.78%
1M Performance:
-13.27%
6M Performance:
+4.62%
1Y Performance:
+39.38%
1-Day Range:
$239.88
$247.58
1-Week Range:
$230.05
$260.91
52-Week Range:
$160.19
$289.46
Insulet Corporation Stock (PODD) Company Profile
Name
Insulet Corporation
Sector
Industry
Phone
978-600-7000
Address
100 NAGOG PARK, ACTON, MA
Compare PODD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
244.67 | 17.18B | 1.98B | 420.90M | 218.20M | 5.84 |
|
ABT
Abbott Laboratories
|
129.89 | 225.27B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.37 | 140.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
363.66 | 138.77B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
92.33 | 118.39B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
67.95 | 39.95B | 5.72B | 4.17B | 259.90M | 6.97 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-25 | Initiated | RBC Capital Mkts | Outperform |
| Nov-06-24 | Initiated | Bernstein | Outperform |
| May-30-24 | Initiated | Redburn Atlantic | Buy |
| May-07-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-21-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-04-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-02-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-21-23 | Upgrade | Citigroup | Neutral → Buy |
| Aug-21-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-11-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-19-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Jul-28-20 | Initiated | Wells Fargo | Overweight |
| Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-03-20 | Initiated | BofA/Merrill | Neutral |
| Mar-31-20 | Downgrade | Berenberg | Buy → Hold |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-10-19 | Initiated | CFRA | Sell |
| Oct-23-19 | Initiated | Stifel | Hold |
| Oct-18-19 | Downgrade | Canaccord Genuity | Buy → Hold |
| Oct-14-19 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-04-19 | Downgrade | UBS | Buy → Neutral |
| Oct-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-06-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-10-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-06-19 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-20-18 | Initiated | Berenberg | Buy |
| Feb-22-18 | Reiterated | Barclays | Overweight |
| Jan-08-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Nov-03-17 | Upgrade | Canaccord Genuity | Hold → Buy |
| Sep-15-17 | Initiated | Barclays | Overweight |
View All
Insulet Corporation Stock (PODD) Latest News
When the Price of (PODD) Talks, People Listen - Stock Traders Daily
Keybank National Association OH Purchases Shares of 840 Insulet Co. (NASDAQ:PODD) - Defense World
SBI Securities Co. Ltd. Buys New Shares in Insulet Co. (NASDAQ:PODD) - Defense World
Jones Financial Companies Lllp Grows Position in Insulet Co. (NASDAQ:PODD) - Defense World
Insulet (NasdaqGS:PODD) Declines 12% After Earnings Reveal Net Income Decrease - Yahoo Finance
Insulet to Host Investor Day on June 5, 2025 - 01Net
Insulet Investor Day 2025: Inside the Future of Tubeless Insulin Pump Technology - StockTitan
Insulet Corp extends deal with NXP USA, amends terms - Investing.com India
Insulet Corp extends deal with NXP USA, amends terms By Investing.com - Investing.com South Africa
Smartleaf Asset Management LLC Purchases 108 Shares of Insulet Co. (NASDAQ:PODD) - Defense World
Insulet (NASDAQ:PODD) shareholders YoY returns are lagging the company's 15% five-year earnings growth - Yahoo Finance
Insulet (NASDAQ:PODD) Earns Outperform Rating from Analysts at Royal Bank of Canada - Defense World
Mutual of America Capital Management LLC Trims Stock Holdings in Insulet Co. (NASDAQ:PODD) - Defense World
Insulet Corp. to Host Earnings Call - ACCESS Newswire
Insulet Corporation to Host Earnings Call - ACCESS Newswire
Insulet Co. (NASDAQ:PODD) Receives $289.06 Consensus Target Price from Analysts - Defense World
RBC Capital Initiates Coverage of Insulet (LSE:0ADR) with Outperform Recommendation - Nasdaq
RBC Capital sets Insulet stock Outperform with $340 price target By Investing.com - Investing.com South Africa
RBC Capital Initiates Coverage of Insulet (PODD) with Outperform Recommendation - Nasdaq
RBC Capital sets Insulet stock Outperform with $340 price target - Investing.com
RBC Initiates Insulet at Outperform With $340 Price Target -March 06, 2025 at 05:54 am EST - Marketscreener.com
Insulet Co. (NASDAQ:PODD) Holdings Lowered by Truist Financial Corp - Defense World
Insulet Corporation: Leveraging Direct-to-Consumer Channels To Boost Product Awareness & Usage! - Smartkarma
Insulet Co. (NASDAQ:PODD) Sees Large Decrease in Short Interest - Defense World
Insulet (NASDAQ:PODD) & PAVmed (NASDAQ:PAVM) Head-To-Head Review - Defense World
Y Intercept Hong Kong Ltd Reduces Holdings in Insulet Co. (NASDAQ:PODD) - Defense World
What's Driving the Market Sentiment Around Insulet? - Benzinga
Guru Fundamental Report for PODD - Nasdaq
Insulet Sales Keep Rising - FX Empire
Insulet May Face Choice: $452M Award Or Stifling Rival - Law360
Insulet Stock Outlook: Is Wall Street Bullish or Bearish? - MSN
Bernstein raises Insulet stock price target to $335 from $315 By Investing.com - Investing.com Nigeria
Agree To Buy Insulet At $270, Earn 11% Annualized Using Options - Nasdaq
$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today - Benzinga
Bernstein raises Insulet stock price target to $335 from $315 - Investing.com India
Insulet Corporation (PODD) PT Raised to $335 at Bernstein; 'Strong Q4, Great Setup for 2025' - StreetInsider.com
Redburn Atlantic Adjusts Price Target on Insulet to $315 From $300, Keeps Buy Rating - Marketscreener.com
Bernstein Adjusts Price Target on Insulet to $335 From $315, Keeps Outperform Rating - Marketscreener.com
Insulet targets 16%-20% U.S. Omnipod growth for 2025 with expanded type 2 diabetes market reach - MSN
Insulet’s Revenue Surpasses $2 Billion with Strong Growth - TipRanks
Insulet Q4 2024 revenue up 17.2% to USD 597.5M - Medical Buyer
Insulet Stock: Aiding Patients And Investors (NASDAQ:PODD) - Seeking Alpha
Insulet Earnings: What To Look For From PODD - MSN
Insulet’s Earnings Highlight Omnipod Success Amid Challenges - TipRanks
Insulet's Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst - AOL
Insulet Updates Equity Agreements for Fiscal 2025 - TipRanks
Insulet stock price target raised to $293 by Stifel - Investing.com Canada
Wells Fargo Adjusts Insulet Price Target to $322 From $305 -February 21, 2025 at 09:22 am EST - Marketscreener.com
Citigroup Adjusts Insulet Price Target to $355 From $310 -February 21, 2025 at 09:21 am EST - Marketscreener.com
Stifel Nicolaus Adjusts Insulet Price Target to $293 From $245 -February 21, 2025 at 09:21 am EST - Marketscreener.com
BTIG Research Adjusts Insulet Price Target to $310 From $300 -February 21, 2025 at 09:19 am EST - Marketscreener.com
Insulet Corporation Stock (PODD) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.40%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):